✦ LIBER ✦

[Principles and Practice] Molecular Aspects of Hematologic Malignancies || Peritransplantation Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia

✍ Scribed by Witt, Michal; Dawidowska, Malgorzata; Szczepanski, Tomasz

Book ID: 119996376
Publisher: Springer Berlin Heidelberg
Year: 2012
Weight: 195 KB
Category: Article
ISBN: 3642294677
DOI: 10.1007/978-3-642-29467-9_16

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[Principles and Practice] Molecular Aspe

[Principles and Practice] Molecular Aspects of Hematologic Malignancies || Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia

✍ Witt, Michal; Dawidowska, Malgorzata; Szczepanski, Tomasz 📂 Article 📅 2012 🏛 Springer Berlin Heidelberg ⚖ 280 KB

[Principles and Practice] Molecular Aspe

[Principles and Practice] Molecular Aspects of Hematologic Malignancies || Molecular Diagnostics of Acute Myeloblastic Leukemia

✍ Witt, Michal; Dawidowska, Malgorzata; Szczepanski, Tomasz 📂 Article 📅 2012 🏛 Springer Berlin Heidelberg ⚖ 398 KB

Role of Minimal Residual Disease Monitor

Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia

✍ Campana, Dario 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 422 KB

Should Minimal Residual Disease Monitori

Should Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia be Standard of Care?

✍ Dario Campana 📂 Article 📅 2012 🏛 Current Science Inc. 🌐 English ⚖ 178 KB

Detection of minimal residual disease in

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

✍ Gaipa, Giuseppe; Basso, Giuseppe; Biondi, Andrea; Campana, Dario 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

Monitoring of minimal residual disease i

Monitoring of minimal residual disease in acute myeloid leukemia

✍ Wolfgang Kern; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 587 KB

## Abstract Two highly sensitive methods, multiparameter flow cytometry (MFC) and real‐time quantitative PCR (RQ‐PCR), are increasingly used to monitor minimal residual disease (MRD) and to guide risk‐adapted management in acute myeloid leukemia (AML). An independent prognostic impact has been demo